Summary:
In adults with type 2 diabetes receiving 1-2 antidiabetic medications, once-weekly semaglutide significantly improved glycemic control and was well tolerated compared to alternative treatments in usual clinical practice, though it was associated with gastrointestinal side effects typical of GLP-1 receptor agonists.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes in the United States receiving 1-2 antidiabetic medications needing treatment intensification. |
| Intervention | Once-weekly semaglutide administered as part of routine clinical care for type 2 diabetes management. |
| Comparison | Alternative glucose-lowering therapies used in real-world clinical settings, including other antidiabetic medications. |
| Outcome | Semaglutide demonstrated significant improvements in glycemic control and treatment tolerability compared to alternatives, with an expected profile of gastrointestinal side effects consistent with GLP-1RA class agents. |
Source: Buse, John B., et al. “Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial.” Read article here.
